Background: The gene encoding phosphatidylinositol-4-phosphate 5-kinase (PIP5K1C) has been recently implicated in pain regulation. Interestingly, a recent cross-tissue and cross-phenotypic epigenetic analysis identified the same gene in alcohol use disorder (AUD). Given the high comorbidity between AUD and chronic pain, we hypothesized that genetic variation in PIP5K1C might contribute to susceptibility to AUD.
A LCOHOL USE DISORDER (AUD) is characterized by excessive and chronic use of alcohol which leads to negative physiological, psychological, and societal consequences and contributes to nearly 4% of deaths worldwide (American Psychiatric Association, 2013; Rehm et al., 2009 Rehm et al., , 2014 Stahre et al., 2014) . While the pathophysiology of AUD is not yet fully understood, there is strong evidence suggesting a genetic component in addition to environmental factors (Tawa et al., 2016) . Twin studies have established that AUD heritability ranges from 40 to 70% (Agrawal and Lynskey, 2008; Enoch and Goldman, 2001; Kendler et al., 2012) . Adoption studies have also suggested that developing alcoholism in adoptees is more associated with their biological parents than with their adoptive parents (Heath, 1995; Sigvardsson et al., 1996) . Despite the strong evidence supporting genetic factors underlying AUD etiology, identifying universal genetic risk variants has been challenging (Tawa et al., 2016) . Several factors contribute to this difficulty, including diverse clinical phenotypes, complex genetic architecture, and involvement of multiple genes with small effect sizes. In addition, the presence of rare and de novo genetic mutations and epigenetic effects further complicate the identification of genetic risk variants for AUD (Robison and Nestler, 2011; Tawa et al., 2016) .
A recent cross-tissue and cross-phenotypic epigenetic analysis of genomewide methylomic variation in AUD identified the phosphatidylinositol-4-phosphate 5-kinase (PIP5K1C) gene as a top target associated with AUD (Lohoff et al., 2017) . PIP5K1C is highly expressed in the brain (Wright et al., 2014) and regulates receptor-mediated calcium signaling, actin cytoskeleton dynamics, and synaptic vesicle trafficking (van den Bout and Divecha, 2009; Di Paolo et al., 2004; Legate et al., 2012; Ling et al., 2002; Unoki et al., 2012; Vasudevan et al., 2009; VolpicelliDaley et al., 2010; Wang et al., 2004 Wang et al., , 2007 Xu et al., 2010; Yu et al., 2011) . Above all, PIP5K1C plays a vital role in production of the protein signaling substrate, phosphatidylinositol 4,5-biphosphate (PIP 2 ) (Di Paolo et al., 2004; White et al., 2013; Wright et al., 2014) . PIP 2 is found in dorsal root ganglia neurons of mice and, following hydrolysis, may initiate multiple pain signaling pathways. Due to its role in PIP 2 production, PIP5K1C has been implicated as a critical regulator of nociceptive signaling and sensitization and may be a therapeutic target for chronic pain (Wright et al., 2014) .
The potential role of epigenetic regulation of PIP5K1C by alcohol is intriguing given the high comorbidity between AUD and chronic pain (Apkarian et al., 2013b; Egli et al., 2012; Katon et al., 1985; Zale et al., 2015) . Previous research estimates that 32.6 million American adults currently meet criteria for an AUD and that 25.3 million American adults experience daily chronic pain (Grant et al., 2015; Nahin, 2015) . Therefore, the overlap between individuals suffering from AUD and chronic pain is significant. In a study of treatment-seeking AUD patients, 73% individuals who identified alcohol as their drug of choice reported experiencing moderate-to-severe pain in the previous 30 days (Larson et al., 2007) . Another study found that problem drinkers reported a higher prevalence of pain in the past 30 days compared to nonproblem drinkers (Brennan et al., 2005) . Additionally, preclinical research indicates that alcohol preference and pain covary in rodents genetically selected for alcohol consumption (Chester et al., 2002; Kampov-Polevoy et al., 1996; Kimpel et al., 2003) . Despite the high comorbidity of AUD and chronic pain, the underlying neurobiology is poorly understood.
Several candidate genes have been suggested to affect systems involved in alcohol dependence and pain (Bardin et al., 2009; Grande et al., 2004; Mobascher et al., 2010; Nilsen et al., 2007; Scarinci et al., 1994; Tiihonen et al., 1999; Van Houdenhove and Luyten, 2006; Wang et al., 2001; Zubieta et al., 2003) . One of the most studied genetic targets is the lopioid receptor encoded by the l-opioid receptor 1 gene (OPRM1). The l-opioid receptor regulates analgesic response to pain and also mitigates the rewarding effects of many drugs (Crist and Berrettini, 2014) . Furthermore, naltrexone, an FDA-approved drug antagonizing l-opioid receptor, reduced alcohol self-administration in animal models and alcohol craving and relapse in clinical populations experiencing AUD (Altshuler et al., 1980; Myers et al., 1986; O'Malley et al., 1992; Volpicelli et al., 1986 Volpicelli et al., , 1992 . Naltrexone prescribed at low doses has been used for chronic pain treatment (Hota et al., 2016) . OPRM1 A118G is the most common and studied nonsynonymous single nucleotide polymorphism (SNP) with a global minor allele, G, frequency of 19% (Crist and Berrettini, 2014) . In preclinical studies, humanized transgenic mouse models for the 118A>G SNP in the OPRM1 gene have been widely used to investigate effects of its genetic variation on sensitivity to pain, analgesic effect of opioids, and alcohol addiction (Mura et al., 2013) . The A118G genetic variant in humans affects pain sensitivity and is a major determinant of striatal dopamine response to alcohol (Bonenberger et al., 2015; Crist and Berrettini, 2014; Fillingim et al., 2005; Lotsch et al., 2006; Ramchandani et al., 2011; Vossen et al., 2010) . Therefore, using the mouse models, it may be possible to explain a complicated mechanism by which alcohol may work as an analgesic although chronic heavy drinking is often linked to chronic pain.
To investigate the role of PIP5K1C in alcohol dependence, we conducted a case-control association study, including discovery and replication cohorts. In addition, we used a humanized OPRM1 A118G transgenic mouse model to explore the interaction of alcohol, OPRM1 genetic variation, and PIP5K1C expression.
MATERIALS AND METHODS

Genetic Association Analysis of PIP5K1C in a Clinical Population
A total of 915 individuals with AUD and 461 healthy controls were recruited to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health in Bethesda, Maryland. A total of 812 individuals were of European ancestry (EA) (488 AUD cases, 324 controls), and a total of 564 individuals were of African ancestry (AA) (427 AUD cases, 137 controls). Alcohol dependence was diagnosed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) (First et al., 2007) . Subjects were diagnosed with DSM-IV alcohol dependence (AD; American Psychiatric Association, 1994), but we used AUD throughout the manuscript for clarity.
Sixteen common PIP5K1C SNPs were extracted from genotype data generated using the Illumina Human OmniExpress-12 and Illumina Human OmniExpressExome v1.2 arrays (Illumina Inc., San Diego, CA). After confirming Hardy-Weinberg equilibrium, exploratory v 2 tests were performed using PLINK version 1.07 (Purcell et al., 2007) . The Benjamini-Hochberg procedure for false discovery rate was used to correct for multiple comparisons.
In addition, linear regression models were used to explore a variety of alcohol-related phenotypes. These phenotypes were severity of alcohol dependence (as measured by the Alcohol Dependence Severity [ADS] score) (Skinner and Allen, 1982) , heavy drinking days in the previous 90 days (as measured by the Timeline Follow Back [TLFB]) (Sobell and Sobell, 1992) , average drinks per day in the previous 90 days (as measured by the TLFB), Clinical Institute Withdrawal Assessment-Alcohol revised (CIWA-Ar) score (Sullivan et al., 1989) , alcohol craving (as measured by the Penn Alcohol Craving Scale) (Flannery et al., 1999) , severity of nicotine dependence (as measured by the Fagerstrӧm Test for Nicotine Dependence [FTND]) (Heatherton et al., 1991) , depressive symptoms (as measured by Comprehensive Psychopathological Rating Scale [CPRS]) (Mattila-Evenden et al., 1996) , anxiety (as measured by the CPRS) (Svanborg and Asberg, 1994) , neuroticism (as measured by the Neuroticism-Extraversion-Openness Personality Inventory) (Costa and McCrae, 1992) , and trait anxiety (as measured by the State-Trait Anxiety Inventory) (Spielberger, 2010) . Age, gender, and ancestry informative markers (AIM) for AA and EA were used as covariates.
Haplotype analyses were conducted using both PLINK and HaploView software (Barrett et al., 2005) with haplotype blocks defined using the default D ' /LOD method in Haploview. Haplotype association tests for alcohol dependence were conducted in PLINK and were corrected for multiple comparisons using permutation tests (10,000 permutations).
Exploratory v 2 tests, using the same methods as described above, were replicated using data from the Study of Addiction: Genetics and Environment (SAGE) database. SAGE is a component of the Gene Environment Association Studies initiative (GENEVA), a genomewide association study of common genetic variants that may be related to addiction (dbGaP accession phs000092.v1.p1). Of the 16 SNPs used in the NIAAA sample, 15 (all but rs12984273) were available in the SAGE database. Whole genotype genotyping was completed using the Illumina ILMN-Human-1 platform. A total of 2,635 individuals were of EA (1,244 AUD cases, 1,391 controls), and a total of 1,166 individuals were of AA (671 AUD cases, 495 controls).
DNA methylation levels were generated on Illumina Human Methylation 450 microarrays in a subset of individuals as published previously (Lohoff et al., 2017) . PIP5K1C promoter probe cg17845617, previously associated with AUD in brain and blood in our previous work (Lohoff et al., 2017) , was assessed for the association of genotype data with general linear models.
PIP5K1C Expression in OPRM1 Mouse Model
We used a humanized mouse line in which OPRM1 was replaced with either the major 118A allele or 118G SNP from human exon 1 of OPRM1. These mice were bred at the NIAAA animal facility. Mice heterozygous for the respective human allele were bred to homozygosity to establish the h/mOPRM1-118AA and h/ mOPRM1-118GG lines. Methods used to create these humanized mouse lines were previously described elsewhere (Ramchandani et al., 2011) . Of the 12 knock-in mice and 12 wild-type mice, half were treated with a single dose of 2 g/kg ethanol (EtOH) and half were treated with a single dose of saline.
Briefly, 30 minutes after EtOH or saline injection, the animals were deeply anesthetized with pentobarbital sodium (50 mg/kg, i.p.) before being transcardially perfused with 50 ml of ice-cold saline (0.9% NaCl) and 150 ml of 4% paraformaldehyde (PFA). Following perfusion, brains were removed, postfixed in 4% PFA for 2 hours, dehydrated in a 30% sucrose solution for 48 hours, snap frozen in powdered dry ice, and stored at À80°C until further use. Coronal sections (40 lm) of the regions of interest were taken by a cryostat (Leica CM3050; Leica Microsystem Inc., Bannockburn, IL), collected in cryoprotectant solution, and stored at À20°C.
The PIP5K1C staining protocol was adapted from the studies by Wright and colleagues (2014) . Briefly, free-floating sections were washed with 0.1 M PBS and then incubated for 15 minutes with 3% H 2 O 2 in 0.1 M PBS. Tissue was then preblocked in 0.1 M PBS containing 0.2% Triton X-100 and 5% normal goat serum for 30 minutes. Sections were incubated in the primary antibody rabbit anti-PIP5K1C (VECTASTAIN Elite ABC HRP Kit [Peroxidase, Rabbit IgG], PK-6101; Vector Laboratories, Burlingame, CA) for 2 days at 4°C on a shaker. Negative controls were performed using goat serum 5% without primary antibody. Following incubation, sections were rinsed with 19 PBS (3 times, 5 minutes) and incubated with biotinylated secondary antibody (1:100, goat anti-rabbit vector ABC Elite Kit, PK-6101; Vector Laboratories) for 30 minutes.
After rinsing, the color reaction for light microscopy was performed using first the avidin-biotin peroxidase solution (Vector ABC Elite Kit, PK-6101) and then adding the 3,3 0 -diaminobenzidine tetrahydrochloride (DAB) (D5905; Sigma, St. Louis, MO) according to the manufacturer's instructions, resulting in a brown color staining. Sections were then rinsed with PBS (2 times, 15 minutes), mounted on gelatin-coated slides, and processed the next day through alcohol-xylene for light microscopy examination.
Pictures were taken on a Leica light microscope DM6000CS at 209 or 409 magnification, and BioQuant imaging software (R&M Biometrics, Nashville, TN) was used for cell density analysis. Two coronal sections (2 levels), containing the thalamus and basolateral amygdala (BLA), both left and right side, were analyzed for PIP5K1C positive cells stained as dark brown color for 2 regions (coordinates: BLA-Bregma: À1.06 to À1.94 mm; and thalamusBregma: À1.22 to À1.94 mm._ENREF_41 (Paxinos et al., 2001) . Results are depicted as the positively stained cells per square millimeter. Blue spots were also observed due to unwanted damage to tissues, which we excluded for the analysis.
Data for PIP5K1C positive cells are reported as mean values AE standard error as number per square millimeter. The data from each experiment was analyzed by a Student's t-test. For all statistical analyses, differences between control and experimental groups were considered significant if p < 0.05.
RESULTS
Genetic Association Analysis of PIP5K1C in a Clinical Population
PIP5K1C Genetic Analyses in Discovery Data. Demographic characteristics of the whole NIAAA clinical sample of 915 alcohol-dependent individuals and 461 healthy controls are shown in Table S1 (top). The sample was separated based on ancestry; demographics for a total of 812 individuals of EA (488 AUD cases, 324 controls) and 564 individuals of AA (427 AUD cases, 137 controls) are displayed in Table S1 (top). No alcohol-related phenotypes, tested using linear regression, were significantly associated with a diagnosis of AUD in either the EA or AA groups. Years of education, drinking days in the last 90 days, heavy drinking days in the last 90 days, ADS score, and FTND score differed significantly (p < 0.0001) between cases and controls in both the EA group and the AA group (Table S1 , top).
The genotype information for the 16 PIP5K1C SNPs is shown in Table 1 . Given large differences in AIM European and AIM African scores, we conducted analyses separately and used age, gender, and AIM for AA and EA as covariates. Hardy-Weinberg equilibrium was not significantly deviated in the population (data not shown). The single marker association analyses revealed that 1 SNP (rs12460780) was significantly associated with a diagnosis of AUD in the EA group (Table 1, top) . However, this association did not hold after correction for multiple comparisons. In the AA sample, 9 SNPs (rs4807493, rs10405681, rs2074957, rs10432303, rs757454, rs8109485, rs1476592, rs10419980, and rs4432372) were indicated as significantly associated with a diagnosis of AUD (Table 1 , bottom). Of these 9 SNPs, 8 remained significantly associated with AUD after correction for multiple comparisons (rs4807493, rs10405681, rs2074957, rs10432303, rs8109485, rs1476592, rs10419980, and rs4432372) (Table 1, bottom).
We previously identified higher DNA methylation levels in AUD subjects at a PIP5K1C promoter CpG, cg17845617 (Lohoff et al., 2017) . Using a subset of 70 controls, we identified significant associations after Bonferroni correction for multiple comparisons of rs4807493, rs8109485, rs1476592, and rs10419980 as methylation quantitative trait loci (mQTLs) from among the above significant SNPs (Table 2) .
Linkage Disequilibrium Structure in Discovery Data. To confirm our single marker association finding, haplotype analyses were run separately for EA and AA samples. Four main haplotype blocks were found based on the linkage disequilibrium (LD) plots for the 16 SNPs that span the PIP5K1C gene. Haplotype structure analyses revealed that the LD plots for the EA and AA groups differed, indicating different haplotype structures in AA and EA populations (Fig. S1 ). Haplotype structures of the 2 subgroups are shown with D' (Fig. S1a,c) and R 2 (Fig. S1b,d ) values.
Haplotype-Based Association in Discovery Data. Haplotype-based association tests were also run separated by ancestry to look for associations between haplotypes and AUD (Table S2 ). In the EA sample, the block 1 haplotype GGAG (frequency = 0.372, p = 0.0606) and the block 4 haplotype AG (frequency = 0.0609, p = 0.0593) were nearly significantly associated with AUD. The haplotype AG contains alleles from 1 SNP (rs12460780) found to be significant in the single SNP association prior to accounting for multiple comparisons. However, similar to the single SNP association test, the significance of the AG haplotype did not withstand correction for multiple comparisons.
In the AA sample, the block 2 haplotype AAG (frequency = 0.319) was significantly associated with AUD (p < 0.01) (Table S3 ). This result is consistent with the single marker association test. That is, the haplotype AAG contains alleles from 3 SNPs (rs2074957, rs10432303, and rs757454) that were found to be significantly associated with AUD. Furthermore, the block 3 haplotype GG (frequency = 0.291) was significantly associated with AUD (p < 0.01) in the AA sample. This result is again consistent with results found in the single marker analyses as the haplotype GG contains alleles from 2 SNPs (rs8109485 and rs11672559) that were found to be significantly associated with AUD.
PIP5K1C Genetic Analyses in Replication Data. Demographic characteristics for the SAGE sample, in which 2,635 individuals were of EA (1,244 AUD cases, 1,391 controls) and 1,166 individuals of AA (671 AUD cases, 495 controls), are shown in Table S1 (bottom). No alcohol-related phenotypes, tested with linear regression, were significantly associated with a diagnosis of AUD in either the EA or AA samples (Table S1 , bottom).
The genotype information for the 15 PIP5K1C SNPs is shown in Table 3 . Given the results in our discovery analysis, we conducted analyses separated by ancestry. The single marker association analyses did not reveal significant associations between the 15 SNPs and AUD diagnosis in either the EA or AA samples (Table 3) .
PIP5K1C Expression in OPRM1 Mouse Model
To confirm whether alcohol stimulates PIP5K1C expression and genetic variants of OPRM1 differentiate the expression, we injected a single dose of 2 g/kg of EtOH to OPRM1 humanized mouse lines with either the major 118A or minor 118G allele SNP, h/mOPRM1-118AA and h/mOPRM1-118GG mice, and performed immunohistochemistry to examine PIP5K1C expression. The 118A>G SNP in OPRM1 gene leads to altered pain threshold and analgesic effect because of changes in the opioid receptor expression and signaling cascades, which may affect PIP5K1C expression by alcohol (Mura et al., 2013; Walter et al., 2013) .
In mice acutely treated with EtOH, there was significantly higher PIP5K1C expression in both the thalamus and BLA (p < 0.05) than in saline-treated mice (Fig. 1) . However, interaction was not observed between genotype and group in neither the thalamus nor the BLA. Thus, there were no significant differences in PIP5K1C expression between AA and GG mice in either the alcohol or saline-treated mice in both brain regions (Fig. 1B,D) .
DISCUSSION
In this study, we explored, for the first time, the association between PIP5K1C variants and AUD. We found in our discovery clinical data an association between common PIP5K1C variants and AUD in individuals of African American descent. The haplotype analysis confirmed the results of our initial single SNP association and indicated that SNPs within the PIP5K1C gene were associated with a diagnosis of AUD in the AA group. The 2 most significant (p < 0.01) SNPs that withstood correction for multiple comparisons and were confirmed by the haplotype analysis were rs10432303 and rs8109485. Both SNPs are intronic variants that are near a repeating element. However, no association between AUD and PIP5K1C variants was observed in the EA sample. It is possible that other ethnicity-specific genetic background differences could have an effect on PIP5K1C variants, and thus, an association between AUD and PIP5K1C expression was only observable in the AA sample.
Our findings in our discovery clinical data set were not observed in our larger replication data set. Thus, we did not conduct a haplotype analysis in the replication sample. One potential confounding factor in our study might have been a spurious association due to population stratification. However, we carefully controlled for this potential effect using AIM scores. Furthermore, clinical heterogeneity may have confounded the results, as some cases had other substance dependence, such as cocaine, cannabis, or opioid, as well as other psychiatric comorbidities: Different individuals had different types of drug use or psychiatric disorders, thus comorbidities were not consistent across participants. Another limitation was that in both our discovery and replication samples, the case and control groups were not matched exactly regarding age and gender. In the NIAAA discovery sample, the majority of both cases and controls in the AA and EA groups were male. However, in the SAGE replication sample, while the majority of cases in the AA and EA groups were male, the majority of the controls of both subgroups were females. Consequently, we statistically controlled for gender, in addition to age, in our analyses. Further research with case and control groups matched for age and gender is recommended. Given the recent report of possible epigenetic regulation of PIP5K1C in AUD (Lohoff et al., 2017) , we performed a cursory analysis in a small subset of control individuals to assess the potential for the identified genotypes to act as mQTLs. Not surprisingly, 4 of the 8 SNPs associated with AUD after correction for multiple testing were significantly associated with PIP5K1C promoter DNA methylation, suggesting a portion of alcohol-related epigenetic associations identified previously may be affected by genetic variation. Interestingly, according to the GTEx database (GTExConsortium, 2015) , all of the SNPs associated with PIP5K1C methylation were also markedly associated with expression in different types of tissues (data not shown here but available on the GTEx Porter, http://gtexportal.org). Only rs10419980 was, however, associated with brain expression, supporting the potential biological relevance of these variants. In all cases, homozygotes and heterozygotes were associated with lower PIP5K1C DNA methylation. In light of our previous observations of AUD-associated DNA methylation increases, these findings are consistent with a protective effect of the ancestral allele. Furthermore, these findings are consistent with the observations in the European American sample where the odds ratios for the minor allele are >1 as opposed to those in the African American sample. These data further suggest that controlling for underlying genetic architecture in epigenetic studies is critical to interpreting the results independent of confounds potentially associated with different ancestry. In the future, additional studies in larger cohorts are needed to evaluate to what degree epigenetic variation in combination with genetic variation could contribute to susceptibility to AUD and pain.
Although the comorbidity between AUD and chronic pain has been well documented, a strong genetic risk variant has not yet been identified (Apkarian et al., 2013b; Egli et al., 2012; Katon et al., 1985; Zale et al., 2015) . Research indicates that the OPRM1 A118G polymorphism is implicated in both pain and AUD, but evidence supporting its role as a genetic link underlying chronic pain and AUD comorbidity is not strong. Given the role of PIP5K1C in pain signaling, we used the transgenic humanized mouse line in which the OPRM1 gene was replaced with the major 118A human allele of OPRM1. The OPRM1 A118G is understood to play a role in modulating pain and alcohol, but the underlying neurobiology is not yet fully understood. In order to create sample homogeneity and prevent possible confounding factors, we used mice that were bred to homozygosity to establish the h/mOPRM1-118AA line. The results from our mouse model provide evidence of a relationship between EtOH treatment and PIP5K1C expression in both the BLA and thalamus. No interaction was observed between genotype and treatment group, indicating that the OPRM1 A118G polymorphism is not involved in mediating PIP5K1C expression. Inhibition of respective receptors mediating the pain response has not produced enough analgesic effect on chronic pain. It is likely that other convergent signaling pathways beyond the receptor level play an important role in explaining the underlying pain mechanism in AUD (Gold and Gebhart, 2010) . Alternatively, the A118G genotype (rs1799971) in OPRM1 gene by itself may not be closely associated with addictions. When cis-expression QTL SNPs were analyzed for association with heroin addiction, 4 SNPs (rs9478495, rs3778150, rs9384169, and rs562859) in OPRM1 intron 1 were significantly associated. Notably, haplotype analyses revealed that the A allele of the functional genetic variant (rs1799971) was significantly correlated with the addiction only when rs3778150-C was present (Hancock et al., 2015) . In a genome-wide association study, rs73568641, located at upstream of the OPRM1 gene, was highly associated with a therapeutic methadone dose, a selective l-opioid receptor agonist for treatment of opioid dependence (OD), in OD subjects (Smith et al., 2017) . Therefore, other unknown genetic variants in the OPRM1 gene or a neighboring gene may participate in PIP5K1C expression by alcohol.
Mice shortly treated with EtOH exhibited significantly higher PIP5K1C expression than control mice treated with saline. Our results are particularly interesting because our case group treated with a single injection of 2 g/kg of EtOH exhibited significantly higher PIP5K1C expression than control mice treated with saline. This may indicate that acute alcohol exposure affects PIP5K1C expression. Our study employed an acute injection of EtOH as an exploratory measure to determine whether an interaction between alcohol, PIP5K1C, and OPRM1 expression was possible. This was based on results from the original study piloting the use of the h/mOPRM1-118AA line which indicated that a single injection of alcohol was associated with substantial dopamine release (Ramchandani et al., 2011) . Future research should investigate the effect of chronic EtOH exposure on targeted PIP5K1C expression. Additionally, our analysis was limited to thalamus and BLA given the well-established role of the thalamus in nociception signaling and that of the BLA in cue-induced alcohol seeking (Apkarian et al., 2013a; Head and Holmes, 1911; Jones, 2007; Yen and Lu, 2013) .
Future research could expand this analysis to other brain regions relative to pain signaling such as the cingulate cortex. Other limitations of our study were that we did not perform behavior tests in our mouse model and that we could not analyze a pain index in our clinical populations based on PIP5K1C SNPs due to a lack of pain history data. Including a behavioral task measuring pain sensitivity by PIP5K1C and alcohol or histories of pain by the genotypes in AUD would lend to a more complete understanding of the interaction of alcohol, pain, and PIP5K1C expression.
To the best of our knowledge, using a translational research approach, our data are the first to reveal the relationship between AUD and PIP5K1C genetic variants, specifically in the AA population from the discovery sample. Thus, our study implicates PIP5K1C as an interesting new target for the investigation of the genetic link underlying comorbid AUD and chronic pain.
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